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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Mexican Span-
ish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 100 JIA patients (16% systemic, 16% oligoarticular, 30% RF positive 
polyarthritis, 38% other categories) and 99 healthy children, were enrolled at the paediatric rheumatology department of the 
Hospital General de Mexico. The JAMAR components discriminated well healthy subjects from JIA patients. However, there 
was no significant difference between healthy subjects and their affected peers in school related problem variable. All JAMAR 
components revealed good psychometric performances. In conclusion, the Mexican Spanish version of the JAMAR is a valid 
tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Mexican Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
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parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drugs side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Mexican Spanish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from October 2011 
to June 2012. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
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scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Mexican Spanish parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Mexican Spanish JAMAR was fully cross-culturally 
adapted from the standard English version with 3 forward 
and 2 backward translations with a concordance for 118/123 
translations lines (95.9%) for the parent version and 120/120 
lines (100%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). The 
texts of the parent JAMAR and of the child JAMAR were 
unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 99 healthy children (total of 
199 subjects), were enrolled. Patients recruited for the study 
were mainly attended the Hospital General de México, but 
there also referrals from the Shriners Hospital in Mexico 
City and the Clinic for the Diagnosis and Treatment of the 
Rheumatic Diseases (CLIDITER = Clinica para el Diagnos-
tico y Tratamiento de las Enfermedades Reumaticas). In the 
100 JIA subjects, the JIA categories were 16% with systemic 
arthritis, 16% with oligoarthritis, 20% with RF negative 
polyarthritis, 30% with RF positive polyarthritis, 1% with 
psoriatic arthritis, 16% with enthesitis related arthritis and 
1% with undifferentiated arthritis (Table 1).
A total of 193/199 (97%) subjects had the parent version 
of the JAMAR completed by a parent (100 from parents 
of JIA patients and 93 from parents of healthy children). 
The JAMAR was completed by 181/193 (93.8%) mothers 
and 12/193 (6.2%) fathers. The child version of the JAMAR 
was completed by all the 199 children age 5 or older. Also 
patients younger than 7 years old, capable to assess their 
personal condition and able to read and write, were asked to 
fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st−3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in school related problem variable.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items, 
whereas a reduced number of response choices was used 
for PF item 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for PF item 15 (data not shown). The median number 
of items marked as not applicable was 0% (0–0%) for the PF 
and 0.5% (0–1%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 56% (47–74%) for the PF 
items, 38% (32–40%) for the HRQoL PhH items, and 47% 
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(44–48%) for the HRQoL PsH items. The median ceiling 
effect was 3% (2–8%) for the PF items, 9% (8–13%) for 
the HRQoL PhH items, and 4% (1–6%) for the HRQoL 
PsH items. The median floor effect was 28% for the pain 
VAS, 30% for the disease activity VAS and 27% for the 
well-being VAS. The median ceiling effect was 1% for the 
pain VAS, 1% for the disease activity VAS and 1% for the 
well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 93% 
of the PF items, with the exception of PF item 15, and for 
100% of the HRQoL items.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 100/193) Child (N = 100/199)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 56.0% 69.0%
 HRQoL PhH 38.0% 45.0%
 HRQoL PsH 47.0% 54.0%
 Pain VAS 28.0% 38.0%
 Disease activity VAS 30.0% 38.0%
 Well-being VAS 27.0% 34.0%
Ceiling effect, median
 PF 3.0% 2.0%
 HRQoL PhH 9.0% 6.0%
 HRQoL PsH 4.0% 2.0%
 Pain VAS 1.0% 1.0%
 Disease activity VAS 1.0% 0.0%
 Well-being VAS 1.0% 1.0%
Items with equivalent item-scale correlation 93% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.95 0.92
 PF-HW 0.97 0.95
 PF-US 0.91 0.79
 HRQoL-PhH 0.92 0.91
 HRQoL-PsH 0.85 0.83
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.88 0.82
 HRQoL-PhH 0.91 0.66
 HRQoL-PsH 0.80 0.88
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.6
 HRQoL PhH 0.7 0.7
 HRQoL PsH 0.4 0.4
 Pain VAS 0.5 0.6
 Disease activity VAS 0.5 0.5
 Well-being VAS 0.6 0.5
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Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.95 for PF-LL, 0.97 for PF-HW, 0.91 
for PF-US. Cronbach’s alpha was 0.92 for HRQoL-PhH and 
0.85 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 6.5 days (6–7 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.88). The ICC 
for the HRQoL PhH and for the HRQoL PsH showed an 
almost perfect reproducibility (ICC = 0.91 and ICC = 0.80, 
respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.6 to 0.7 
(median = 0.6). The PF total score best correlation was 
observed with the number of joints with the limitation of 
motion (r = 0.7, p < 0.001). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.6 to 0.7 (median = 0.7), whereas 
for the PsH ranged from 0.3 to 0.5 (median = 0.4). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.8, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.6, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred and 
laboratory measures were 0.5 (0.4–0.6), 0.5 (0.4–0.6), 0.6 
(0.5–0.6), respectively.
Discussion
In this study, the Mexican Spanish version of the JAMAR 
was cross-culturally adapted from the original standard Eng-
lish version with three forward and two backward transla-
tions. According to the results of the validation analysis, the 
Mexican Spanish parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. Notably, 
there was no significant difference between the healthy sub-
jects and their affected peers in the school related problem 
variable. This finding indicates that children with JIA adapt 
well to the consequences of JIA. The PF total score proved 
to discriminate between the different JIA subtypes with chil-
dren with RF positive poly-arthritis having a higher degree 
of disability.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was excel-
lent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Mexican Spanish version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multidi-
mensional assessment of children with JIA.
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